A fiber-eating colon bacterium that turns inulin into butyrate, the fuel for the gut lining. People with healthier guts and better metabolic profiles carry more of it, but the evidence is early and mostly indirect. The reliable way to support it is eating more fermentable fiber; it is not sold as a product. Promising but unproven. (Full Review)

Protocol

Prebiotic (fiber-first) approach

10–20 g/day prebiotic fiber

Inulin/fructo-oligosaccharides and resistant starch from food and supplements combined; the mainstream, evidence-supported route.

Slow titration

Start 2–5 g/day

Increase by 2–3 g every 1–2 weeks; split dosing across meals to reduce gas and bloating.

Best time of day

With or near meals

Pairs the fiber substrate with normal colonic fermentation; no time-of-day advantage for the bacterium itself.

Time to effect

Stable changes & benefit

Weeks to months

Meaningful, stable changes in Roseburia abundance and any downstream benefit typically require sustained intake.

Initial bacterial shifts

Days to a few weeks

Fiber-driven shifts in butyrate-producing bacteria can begin within this window.

Benefits

Medium: Production of butyrate to support the gut barrier

Low: Association with better metabolic and glycemic profiles; association with lower inflammation and healthier gut ecology

Speculative: Gut–brain and neurological support; estrogen metabolism and hormone-related health

Contraindications

Severely immunocompromised individuals (active chemotherapy, neutropenia, transplant recipients on immunosuppression)

People with central venous catheters

Active severe inflammatory bowel disease flares

The critically ill

Pregnant and breastfeeding individuals

Key Interactions

Broad-spectrum antibiotics (amoxicillin, clindamycin, metronidazole, fluoroquinolones such as ciprofloxacin)

OTC laxatives, antacids, or proton-pump-style acid reducers (omeprazole-class)

Prebiotic fibers and butyrate-supporting supplements (inulin, fructo-oligosaccharides, resistant starch, partially hydrolyzed guar gum, tributyrin or sodium butyrate)

Fecal microbiota transplantation and other live probiotics

Risk & Side Effects

Low: Gastrointestinal symptoms from fiber-based approaches

Speculative: Unknown safety of live-biotherapeutic delivery; context-dependent or adverse associations

Monitoring

Marker	Target	Why
Stool Roseburia / butyrate-producer abundance	Within or above lab reference range for butyrate producers	Direct read on the target microbes
Stool short-chain fatty acids (butyrate)	Mid-to-upper end of lab reference range	Reflects functional output of fiber fermentation
High-sensitivity C-reactive protein (hs-CRP)	< 1.0 mg/L	Tracks the low-grade inflammation butyrate may reduce
Fasting glucose and HbA1c	Glucose 70–90 mg/dL; HbA1c < 5.4%	Captures the metabolic outcomes associated with butyrate producers
Fasting insulin	2–6 µIU/mL	Early marker of metabolic health that gut changes may influence

Cadence: Baseline before starting; reassess at 8–12 weeks after a sustained change, then every 6–12 months if continued.

Qualitative Assessment

Digestive comfort: less bloating, more regular and well-formed stools over time
Bowel regularity and transit consistency
Energy levels and post-meal stability
General sense of gut tolerance to fiber as the population adapts

Roseburia inulinivorans for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment